OC-010 Final efficacy and safety in hcv genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin: topaz-i results from the united kingdom and ireland

D Forton; A Ustianowski; R Aspinall; S Ryder; M Aldersley; D Mutimer; F Murray; PA McCormick; J Dillon; G Foster; K Agarwal; M Charafeddine; A Joy; L Liu; R-M Stanica; T Pilot-Matias; M O’Meara; C Pollard; DE Cohen; S Norris

doi:10.1136/gutjnl-2017-314472.10

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

Hosted content
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Alerts

Liver Section Free Papers

OC-010 Final efficacy and safety in hcv genotype 1-infected patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin: topaz-i results from the united kingdom and ireland

Log in using your username and password

Main menu

Log in using your username and password

You are here

Read the full text or download the PDF:

Log in using your username and password